

News Release



For reference purposes only – Japanese version prevails in case of any discrepancy

September 2, 2025

Approval for Marketing Authorization for ECCLOCK gel 5% in Korea for Treatment of Primary Axillary Hyperhidrosis

Kaken Pharmaceutical Co., Ltd. (“Kaken”, head office: Bunkyo-ku, Tokyo; President and Representative Director, Hiroyuki Horiuchi) announced that Dong-Wha Pharm. Co., Ltd. (“Dong Wha”, head office: Seoul; Co-CEOs, Jun Ha Yoo and In Ho Yoon) has obtained approval from MFDS: Ministry of Food and Drug Safety for the marketing authorization in Korea of ECCLOCK gel 5%, a topical formulation drug for primary axillary hyperhidrosis (generic name: sofpironium bromide; product name in Japan: ECCLOCK®).

In June 2023, Kaken and Dong Wha entered into an agreement under which Kaken granted Dong Wha the exclusive right for the development and commercialization of the product in Korea based on its rights to sub-license in certain Asian countries granted by Botanix SB, Inc. (head office: Pennsylvania, USA), and Dong Wha had applied for marketing authorization for Sofpironium Bromide. Dong Wha plans to launch the product at the earliest possible timing.

About Dong Wha

Dong Wha is a Korean pharmaceutical company, listed on the Korean Stock Exchange (000020.KS), with strong capabilities in research and development, manufacturing and marketing and has been providing superior pharmaceutical products in Korea since its foundation in 1897. For more information, please visit <https://www.dong-wha.co.kr/>.

Cautionary notes regarding forward-looking statement

This release contains forward-looking statements on the Kaken group’s business. They are projections based on information available at the time this release was prepared, and may differ from actual results due to a variety of factors. In addition, although this release includes information related to pharmaceutical products (including those under development), these statements are not intended to be advertisement or medical advice.